Pathogenetic Insights from the Treatment of Rheumatoid Arthritis
Lancet 2017;389:2328–37 DOI 10.1016/S0140-6736(17)31472-1
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Lancet 2017;389:2328–37 DOI 10.1016/S0140-6736(17)31472-1
Arthritis Rheumatol. 2017 Oct;69(10):1949-1959. doi: 10.1002/art.40186
Cochrane Database Syst Rev. 2017 May 8;5:CD012657. doi: 10.1002/14651858.CD012657
Ann Rheum Dis 2017;76:1009–19
Ann Rheum Dis 2017;76:998–100
J Med Econ 2017;20:464–73
Rheumatology doi: 10.1093/rheumatology/kex087
Rheumatology. Doi 10.1093/rheumatology/kex068
Ann Rheum Dis Published Online First: 7 April 2017. Doi 10.1136/annrheumdis-20160210561
N Engl J Med. 2017 May 4;376(18):1723-1736. DOI 10.1056/NEJMoa1606910
Tofacitinib, at a dose of 10 mg twice daily, was more effective than placebo for induction of remission and mucosal healing in patients with moderately to severely active ulcerative colitis. Furthermore, maintenance therapy with tofacitinib, at a dose of either 5 mg or 10 mg twice daily, was more effective than placebo in sustaining remission and mucosal healing.